Durvalumab tests membranous staining of PD-L1 on tumor cells as the method for scoring, using the SP263 antibody assay (Ventana), with samples considered positive if ≥25% of tumor cells express PD-L1 [37]. The gene discussed is CD274; the disease is neoplasm.